Symeres acquires Exemplify BioPharma in 2nd US buy this year
26 Oct 2022
VaccineAcquisitionmRNA
Preview
Source: FierceBiotech
Exemplify, which is based in Cranberry, New Jersey, and has 20 employees, provides end-to-end small-molecule chemistry manufacturing and controls services to pharmaceutical and biotech partners.
Symeres has acquired Exemplify BioPharma for an undisclosed price, marking the CRO and CDMO’s second purchase in the U.S. in 2022.
In April, Netherlands-based Symeres snapped up U.S. lipid maker and organic chemistry contractor Organix as part of the company’s efforts to expand its drug discovery business into the lipids market to meet demand from developers of mRNA therapeutics and vaccines. Financial terms of the deal weren't disclosed.
Next in its sights is Exemplify, which is based in Cranberry, New Jersey, and has 20 employees who provide end-to-end small-molecule chemistry manufacturing and controls services to pharmaceutical and biotech partners. Exemplify also offers services in process chemistry, analytical chemistry and formulation development.
“This acquisition, following the addition of Organix earlier this year and our investment plans for all of our R&D facilities, is a further tangible demonstration of Symeres' strategy of building a leading mid-sized transatlantic pharmaceutical R&D service provider for our clients around the world,” Symeres CEO Eelco Ebbers, Ph.D., said in the release.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.